KRTX Karuna Therapeutics Inc.

93.86
+3.74  (+4%)
Previous Close 90.12
Open 90.19
Price To Book 6.37
Market Cap 2,452,573,063
Shares 26,130,120
Volume 326,331
Short Ratio
Av. Daily Volume 260,845
Stock charts supplied by TradingView

NewsSee all news

  1. Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update

    End of Phase 2 meeting scheduled with the U.S. Food and Drug Administration (FDA) with feedback from the meeting expected to be announced in the second quarter Additional data from Phase 2 clinical trial of KarXT

  2. Karuna Therapeutics Appoints Christopher J. Coughlin to its Board of Directors

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  3. Karuna Therapeutics to Participate in Stifel's 2nd Annual CNS Day Virtual Event

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  4. Karuna Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Provides General Business Update

    Met primary endpoint in Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia and demonstrated favorable safety profile with no significant weight gain, somnolence or

  5. Karuna Therapeutics to Present at the Cowen and Company's 40th Annual Health Care Conference

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated in 2020.
KarXT
Acute psychosis in patients with schizophrenia
Phase 1b data due by the end of 2020.
KarXT
Healthy elderly volunteers / dementia-related psychosis
Phase 1b data due mid-2020.
KarXT
Pain in healthy volunteers

Latest News

  1. Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update

    End of Phase 2 meeting scheduled with the U.S. Food and Drug Administration (FDA) with feedback from the meeting expected to be announced in the second quarter Additional data from Phase 2 clinical trial of KarXT

  2. Karuna Therapeutics Appoints Christopher J. Coughlin to its Board of Directors

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  3. Karuna Therapeutics to Participate in Stifel's 2nd Annual CNS Day Virtual Event

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  4. Karuna Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Provides General Business Update

    Met primary endpoint in Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia and demonstrated favorable safety profile with no significant weight gain, somnolence or

  5. Karuna Therapeutics to Present at the Cowen and Company's 40th Annual Health Care Conference

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  6. Karuna Therapeutics Provides Update on its Discovery Research Efforts

    Announces new strategic drug discovery partnership with Charles River Opens new office dedicated to drug discovery and potential development of novel CNS therapeutics Karuna Therapeutics, Inc. (NASDAQ:KRTX), a

  7. Karuna Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  8. Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  9. Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  10. Karuna Therapeutics Announces Proposed Public Offering of Common Stock

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  11. Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

    KarXT Demonstrated Statistically Significant and Clinically Meaningful Improvement in Total PANSS Score at All Time Points Over Five Weeks and was Well-Tolerated Compared to Placebo Improvement in Total PANSS Score at

  12. Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  13. Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update

    Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track with topline data expected in late 2019 Phase 1b clinical trials for the treatment of psychosis in